6.
Park S, Choi J, Lee Y, Noh J, Kim N, Lee J
. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation. Nat Commun. 2024; 15(1):3368.
PMC: 11032360.
DOI: 10.1038/s41467-024-47743-1.
View
7.
Wang W, Lusvarghi S, Subramanian R, Epsi N, Wang R, Goguet E
. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe. 2022; 30(12):1745-1758.e7.
PMC: 9584854.
DOI: 10.1016/j.chom.2022.10.012.
View
8.
Liang C, Raju S, Liu Z, Li Y, Arunkumar G, Case J
. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature. 2024; 630(8018):950-960.
PMC: 11419699.
DOI: 10.1038/s41586-024-07539-1.
View
9.
Yorsaeng R, Atsawawaranunt K, Suntronwong N, Kanokudom S, Chansaenroj J, Assawakosri S
. SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis. Vaccines (Basel). 2023; 11(7).
PMC: 10384814.
DOI: 10.3390/vaccines11071184.
View
10.
Muhlemann B, Trimpert J, Walper F, Schmidt M, Jansen J, Schroeder S
. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants. Proc Natl Acad Sci U S A. 2024; 121(32):e2310917121.
PMC: 11317614.
DOI: 10.1073/pnas.2310917121.
View
11.
Miller J, Hachmann N, Collier A, Lasrado N, Mazurek C, Patio R
. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N Engl J Med. 2023; 388(7):662-664.
PMC: 9878581.
DOI: 10.1056/NEJMc2214314.
View
12.
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C
. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses. 2023; 15(1).
PMC: 9866114.
DOI: 10.3390/v15010167.
View
13.
Lau J, Cheng S, Leung K, Lee C, Hachim A, Tsang L
. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023; 29(2):348-357.
PMC: 9941049.
DOI: 10.1038/s41591-023-02219-5.
View
14.
Puenpa J, Chansaenroj J, Suwannakarn K, Poovorawan Y
. Genomic epidemiology and evolutionary analysis during XBB.1.16-predominant periods of SARS-CoV-2 omicron variant in Bangkok, Thailand: December 2022-August 2023. Sci Rep. 2024; 14(1):645.
PMC: 10770311.
DOI: 10.1038/s41598-023-50856-0.
View
15.
Wang Q, Guo Y, Tam A, Valdez R, Gordon A, Liu L
. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Rep Med. 2023; 4(11):101258.
PMC: 10694617.
DOI: 10.1016/j.xcrm.2023.101258.
View
16.
Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J
. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529.
PMC: 9931576.
DOI: 10.1038/s41586-022-05644-7.
View
17.
Rossler A, Netzl A, Knabl L, Bante D, Wilks S, Borena W
. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nat Commun. 2023; 14(1):5224.
PMC: 10460376.
DOI: 10.1038/s41467-023-41049-4.
View
18.
Knight M, Changrob S, Li L, Wilson P
. Imprinting, immunodominance, and other impediments to generating broad influenza immunity. Immunol Rev. 2020; 296(1):191-204.
DOI: 10.1111/imr.12900.
View
19.
Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer A, Ginn H
. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021; 184(8):2201-2211.e7.
PMC: 7891044.
DOI: 10.1016/j.cell.2021.02.033.
View
20.
Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y
. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023; 14(1):2800.
PMC: 10187524.
DOI: 10.1038/s41467-023-38435-3.
View